T1	Participants 53 93	in postmenopausal breast cancer patients
T2	Participants 429 465	In metastatic breast cancer patients
T3	Participants 610 717	Whether or not patients on adjuvant endocrine treatment might benefit from these drugs is currently unclear
T4	Participants 962 1031	tamoxifen resistance in postmenopausal primary breast cancer patients
T5	Participants 1041 1090	We recollected primary tumor tissue from patients
T6	Participants 2074 2248	Patients whose tumor expresses p-p70S6K, as a marker of downstream PI3K and/or MAPK pathway activation, have a favorable prognosis, but do not benefit from adjuvant tamoxifen
T7	Participants 2315 2361	in these patients needs to be further explored
